ZUG, Switzerland--(BUSINESS WIRE)-- <\/p>\n
PSI CRO, a full-service contract research organization, continues research on differing strains of bacteria in various countries. It is important to know which pathogens and patterns of antibacterial resistance can be found in any particular country when conducting multi-national clinical trials of new antibacterial medicines. Currently, there is a lack of this data for some countries, e.g. for Central and Eastern Europe (CEE). Therefore, at the initiative of the Head, Medical Affairs at PSI, Maxim Belotserkovsky, MD, PhD, and in collaboration with the Russian National Institute of Antibacterial Chemotherapy, a surveillance program aimed at studying typical pathogens and antibacterial resistance patterns in CEE countries was instituted 5 years ago. The next report on this continuing program, Isolation rate and patterns of pathogens isolated from hospitalized patients with community-acquired pneumonia (CAP) in clinical trialswill be presented as a poster at theECCMID meetingApril 27-30 in Berlin. <\/p>\n
About PSI CRO AG:PSIis a privately-held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSIsglobal reachsupports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of their commitment to be the best CRO in the world as measured by their clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300. <\/p>\n<\/p>\n
<\/p>\n
Read more: ZUG, Switzerland--(BUSINESS WIRE)-- PSI CRO, a full-service contract research organization, continues research on differing strains of bacteria in various countries. It is important to know which pathogens and patterns of antibacterial resistance can be found in any particular country when conducting multi-national clinical trials of new antibacterial medicines. Currently, there is a lack of this data for some countries, e.g. Continue reading
\nPSI Announces Experts to Present at 23rd European Congress of Clinical Microbiology & Infectious Diseases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"